Our findings align with these findings, reinforcing the therapeutic potential of targeting STAT3, particularly in PTEN-deficient CRC, where STAT3 appears to play a critical role in activation of oncogenic signaling. This evidence concerns the gene PTEN and colorectal carcinoma.